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Abstract
Background: We aimed to compare effectiveness and safety of non-vitamin K antagonist oral anticoagulants
(NOACs) versus vitamin-K antagonists (VKA) in atrial fibrillation (AF) patients with chronic kidney disease (CKD) not
receiving dialysis.
Methods: By using personal identification numbers, we cross-linked individual-level data from Danish administrative
registries. We identified every citizen with a prior diagnosis of AF and CKD who initiated NOAC or VKA (2011–2017).
An external analysis of 727 AF patients with CKD (no dialysis) was performed to demonstrate level of kidney
function in a comparable population. Study outcomes included incidents of stroke/thromboembolisms (TEs), major
bleedings, myocardial infarctions (MIs), and all-cause mortality. We used Cox proportional hazards models to
determine associations between oral anticoagulant treatment and outcomes.
Results: Of 1560 patients included, 1008 (64.6%) initiated VKA and 552 (35.4%) initiated NOAC. In a comparable
population we found that 95.3% of the patients had an estimated glomerular filtration rate (eGFR) < 59 mL/min.
Patients treated with NOAC had a significantly decreased risk of major bleeding (hazard ratio (HR): 0.47, 95%
confidence interval (CI): 0.26–0.84) compared to VKA. There was not found a significant association between type of
anticoagulant and risk of stroke/TE (HR: 0.83, 95% CI: 0.39–1.78), MI (HR: 0.45, 95% CI: 0.18–1.11), or all-cause
mortality (HR: 0.99, 95% CI: 0.77–1.26).
Conclusion: NOAC was associated with a lower risk of major bleeding in patients with AF and CKD compared to
VKA. No difference was found in risk of stroke/TE, MI, and all-cause mortality.
Keywords: Atrial fibrillation, Chronic kidney disease, NOAC, VKA, Oral anticoagulation
Background
Atrial fibrillation (AF) and chronic kidney disease (CKD)
often coexist [1], and the number of patients suffering
from both conditions is rising globally as a result of an
aging population.
The risk of stroke, systemic thromboembolism (TE)
and myocardial infarction (MI) is higher among such pa-
tients than in AF patients with no renal disease [2, 3]. A
Danish study found that AF patients with non-end-stage
CKD or end-stage CKD had an increased risk of stroke/
TE of 50 and 83%, respectively, compared to patients
without renal disease [2]. Furthermore, the presence of
both disorders increases the risk of bleeding [2], causing
treatment for such patients to be complicated. Oral
anticoagulation (OAC) reduces risk of stroke/TE and all-
cause mortality in the general AF population [4], and AF
patients at high stroke risk are recommended lifelong
therapy with a vitamin-K antagonist (VKA) or non-VKA
OAC (NOAC). NOACs have proven superior or nonin-
ferior to VKA in AF patients in regards of stroke and TE
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prevention, they are prescribed in fixed dosages, and do
not require international normalized ratio (INR) moni-
toring [5]. Both have also proven effective in reducing
the risk of stroke/TE in AF patients with mild to moder-
ate CKD [3, 6], but patients with severe CKD have been
excluded from randomized clinical trials of NOAC vs.
VKA [5, 7]. All NOACs are dependent on renal clearance
[6], which is why there have been concerns regarding effi-
cacy and safety in patients with more advanced CKD.
The aim of this study was to determine whether pa-
tients diagnosed with both AF and CKD can benefit
from NOAC treatment the same way as patients without
CKD can.
Methods
Data sources
Every Danish citizen has a unique civil registration num-
ber, which allows cross-linkage of several nationwide regis-
tries on an individual basis. All discharge diagnoses from
Danish hospitals are registered in the nationwide Danish
National Patient Registry [8]. Every drug dispensed from a
Danish pharmacy is registered in the Danish Prescription
Registry [9]. Civil status, yearly income, and cause of death
is registered in the Danish Civil Registration System [10].
Study population
We identified all Danish citizens with a prior diagnosis
of AF and CKD who initiated OAC between 22nd Au-
gust 2011 (the day that the first NOAC, dabigatran, was
approved in Denmark) and 30th June 2017 (data in our
registries were available until this date). We excluded pa-
tients with valvular AF, defined as mechanical heart
valve or rheumatic heart disease [11]. Additionally, we
excluded patients on dialysis where use of all NOACs
are off-label, and patients initiated on edoxaban because
of the low number of patients, and due to its short
period of time available on the market.
External analysis of CKD diagnosis
Since plasma creatinine measurements were not available
after 2011, we had no data on kidney function in the study
population. We estimated kidney function level by studying
a comparable CKD population. Thus, we created a dataset
of 727 AF patients with CKD (no dialysis) diagnosed be-
tween 1997 and 2011who were first-time initiators of
OAC. All patients in the dataset had one plasma creatinine
measurement within 90 days before initiating OAC. Plasma
creatinine values were registered in databases from either a
general practitioner or from a hospital clinic. eGFR was
calculated using the CKD-EPI equation [12].
Baseline characteristics
Co-medication and co-morbidity were defined as in earl-
ier studies [13, 14]. In brief, co-medication was identified
as prescriptions claimed during the last 180 days before
inclusion in the study, and co-morbidity was identified
from hospital diagnoses during the last 5 years before in-
clusion. All ICD and ATC codes used to define our data-
set are listed in Additional file 1.
Outcomes and follow-up
Patients were followed after initiation of OAC until
whichever of the following occurred first: emigration,
death from any cause, discontinuation/switch of OAC,
30th June 2017, or 1 year after initiation of OAC. We in-
vestigated the following events: i) major bleeding, de-
fined as gastrointestinal, urogenital, airway, intraocular
or intracranial bleeding causing hospitalization [15], ii)
stroke/thromboembolism defined as ischemic or unclas-
sified stroke or systemic arterial thromboembolism [16],
iii) myocardial infarction, and iv) all-cause mortality.
Statistics
Continuous covariates are presented as medians with
interquartile range (IQR), and categorical covariates are
presented as frequencies with percentages. P-value for
differences in baseline characteristics were calculated using
Wilcoxon-Mann Whitney or Chi square test for continu-
ous or categorical variables, respectively. P-value for trend
in initiation patterns over time was calculated using the
Cochran-Armitage test. Cumulative incidence of event ac-
cording to OAC was calculated using the Aalen-Johansen
estimator, with death considered as competing risk. P-
value for difference in cumulative incidence was calculated
using Grey’s test. Cox proportional hazards models were
used to examine the association between use of OAC and
outcome. Models with bleeding as outcome were adjusted
for age, sex, prior bleeding, prior stroke, liver disease,
hypertension, and use of non-steroid anti-inflammatory
drugs, acetylsalicylic acid, adenosine phosphate receptor in-
hibitors (ADPi), and income during the previous year.
Models with stroke/thromboembolism or myocardial in-
farction as outcome were adjusted for age, sex, prior stroke,
heart failure, hypertension, coronary heart disease, diabetes,
and use of acetylsalicylic acid, ADPi and income during the
previous year. Models with all-cause mortality as outcome
were adjusted for age, sex, prior stroke, prior bleeding, cor-
onary heart disease, heart failure, hypertension, diabetes,
liver disease, use of non-steroid anti-inflammatory drugs,
acetylsalicylic acid, ADPi, and income during the previous
year. A Kolmogorov type test was used to examine the pro-
portional hazards assumption, and we tested for interaction
between OAC and relevant variables, including age, sex, in-
come, and treatment with ADPi or acetylsalicylic acid in all
models. G-formula based on the Cox models were used to
calculate standardized absolute risk according to VKA or
NOAC treatment each month during follow-up, and 1000
bootstraps calculated confidence intervals. As sensitivity,
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we calculated hazard ratios (HRs) according to time-
varying OAC instead of OAC at baseline, e.g., patients
could switch exposure status (switch between VKA and
NOAC treatment or vice versa) during follow up. HRs
were also calculated according to OAC among AF patients
with CKD when not censoring at shift or discontinuation.
All analyses were performed with SAS version 9.4, and R
version 3.4.1 [17].
Results
Study population
A study population of 1560 patients with non-valvular
AF and CKD was identified during our study period
from 2011 to 2017 (Fig. 1). From this population, 1008
(64.6%) patients initiated VKA treatment while 552
(35.4%) initiated NOAC treatment. Of these 552 pa-
tients, 302 (54.7%) received apixaban, 170 (30.8%) re-
ceived rivaroxaban, and 80 (14.5%) received dabigatran.
In the NOAC population, 428 patients (77.5%) received
reduced dose. The patients who initiated a NOAC were
more likely to be older and more often women com-
pared to the VKA patients (Table 1). No significant dif-
ferences were found between the two groups of patients
in terms of other co-morbidities or co-medications.
Other baseline characteristics are listed in Table 1.
External analysis of kidney function in a comparable
population
In a comparable population of 727 patients with a diag-
nosis code of AF and CKD, 3 (0.4%) of included patients
had an eGFR > 90mL/min/1.73m2, 31 (4.3%) an eGFR
60–90mL/min/1.73m2, 312 (42.9%) an eGFR 30–59mL/
min/1.73m2, 319 (43.9%) an eGFR 15-29mL/min/
1.73m2, and 62 (8.5%) an eGFR < 15mL/min/1.73m2
(Additional file 2).
In aggregation, 95.3% had an eGFR < 59mL/min/
1.73m2 while 52.4% had an eGFR < 29mL/min/1.73m2.
Risk of stroke/TE, major bleeding, myocardial infarction,
and all-cause mortality
Between 2011 and 2017, a significant increase in initi-
ation of NOAC among AF patients with CKD was ob-
served (p-value for trend < 0.001) (Fig. 2). In 2011, 15%
initiated a NOAC compared to 60% in late 2017.
Table 2 shows adjusted HRs and 1-year standardized
absolute risks of stroke/TE, major bleeding, MI, and all-
cause mortality according to type of OAC.
The 1-year standardized absolute risk of stroke/TE in
AF patients with CKD treated with NOAC was 2.0%
(95% confidence interval (CI): 0.8–3.3%) and for the
group treated with VKA 2.4% (95% CI: 1.4–3.5%). There
was no significant difference between the risk of stroke/
TE among NOAC patients compared to VKA patients
(HR: 0.83, 95% CI: 0.39–1.78).
The 1-year standardized absolute risk of major bleed-
ing in the study population was 2.8% (95% CI: 1.5–4.3%)
among NOAC patients and 5.9% (95% CI: 4.4–7.5%)
among VKA patients. There was a significant association
between major bleeding and type of OAC. Patients re-
ceiving a NOAC had a significant lower risk of major
bleeding compared to patients on VKAs (HR: 0.47, 95%
CI: 0.26–0.84). We found no significant association
Fig. 1 Flowchart of the selection of the study population
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between use of NOAC and risk of MI (HR: 0.50, 95% CI:
0.21–1.19). The 1-year standardized absolute risk of MI
was 1.1% (95% CI: 0.4–2.2%) in the NOAC treated popu-
lation and 2.5% (95% CI: 1.5–3.7%) in the VKA treated
population. The 1-year standardized absolute risk of all-
cause mortality was 23.2% (95% CI: 19.4–27.0%) in AF
patients with CKD on NOAC and 23.3% (95% CI, 20.2–
26.3%) for the ones on VKA. No differences were found
in all-cause mortality between the two groups of patients
(HR: 0.99, 95% CI: 0.77–1.26). Figure 3 illustrates the
standardized absolute risks of stroke/TE, major bleeding,
MI, and all-cause mortality, described above, in the first
year following drug initiation among patients on NOAC
or VKA, respectively. Cumulative incidences of the study
outcomes yielded similar results (Additional file 3).
Sensitivity analyses
Analyses of the study outcomes were repeated with
time-varying OAC, allowing patients to change treat-
ment group after inclusion. These results were similar to
main analyses (Additional file 4). When not censoring at
shift or discontinuation of OAC, outcomes were similar
to main results as well (Additional file 5).
Discussion
This nationwide study examined the risk of stroke/TE,
major bleeding, MI, and all-cause mortality in AF patients
with CKD, comparing patients treated with NOAC to
VKA. We had the following important findings: 1) there
was a significant gradual increase in the use of NOACs
during our study period, 2) NOACs were associated with
Table 1 Baseline characteristics of the study population
Patients receiving VKA (n = 1008) Patients receiving NOAC (n = 552) P value
Median age (IQR) 78.00 (71.00–84.00) 80.00 (72.00–86.00) < 0.001
Male (%) 645 (64.0) 314 (56.9) 0.007
Oral anticoagulation < 0.001
Apixaban (%) 302 (54.7)
Dabigatran (%) 80 (14.5)
Rivaroxaban (%) 170 (30.8)
VKA (%) 1008 (100.0)
Income group (quartiles) < 0.001
1st (lowest) 382 (37.9) 143 (25.9)
2nd 297 (29.5) 165 (29.9)
3rd 208 (20.6) 159 (28.8)
4th (highest) 121 (12.0) 85 (15.4)
Comorbidity
Hypertension 914 (90.7) 494 (89.5) 0.454
Previous stroke (%) 175 (17.4) 102 (18.5) 0.629
Previous bleeding (%) 256 (25.4) 122 (22.1) 0.164
Heart failure (%) 395 (39.2) 195 (35.3) 0.147
Ischemic heart disease (%) 440 (43.7) 231 (42.9) 0.492
Peripheral artery disease (%) 101 (10.0) 63 (11.4) 0.391
Diabetes (%) 260 (25.8) 141 (25.5) 0.962
Liver disease (%) 28 (2.8) 19 (3.4) 0.563
Alcohol abuse (%) 38 (3.8) 31 (5.6) 0.117
Comedication
ADPi (%) 164 (16.3) 107 (19.4) 0.138
Aspirin (%) 537 (53.3) 277 (50.2) 0.264
Statin (%) 503 (49.9) 275 (49.8) 1.000
Beta-blocker (%) 582 (57.7) 303 (54.9) 0.302
RASi (%) 524 (52.0) 294 (53.3) 0.667
NSAID (%) 116 (11.5) 69 (12.5) 0.619
Abbreviations: IQR Interquartile Range, ADPi Adenosine diphosphate inhibitor, VKA Vitamin K antagonist, RASi Renin angiotensin system inhibitor, NOAC
Nonvitamin K oral anticoagulants, NSAID Non-steroid anti-inflammatory drugs
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a significantly lower risk of major bleeding compared to
VKA, 3) there were no significant differences in occur-
rence of MI, stroke/TE or all cause-mortality with NOAC
or VKA, and 4) the risk of death of any cause was almost
one in four following the first year after treatment initi-
ation among patients with AF and CKD.
Efficacy and safety of NOAC vs. VKA
VKAs such as warfarin are cleared mainly by the liver [6],
but there are no randomized studies comparing warfarin
with placebo among patients with moderate or severe
CKD. Warfarin-related hemorrhages increase as creatinine
clearance decreases [6], and time in therapeutic range with
warfarin is often low among patients with CKD, which indi-
cates a need for careful monitoring of these patients or a
different treatment strategy. Our study investigated three
types of alternatives to warfarin for stroke prevention
among AF patients with CKD, specifically apixaban, rivar-
oxaban, and dabigatran. The renal clearance of these
NOACs ranges between 27 and 80% [6], and there has been
concern that reduced drug-elimination due to impaired
GFR may lead to an increased risk of severe bleedings. Our
findings do not support this concern, as NOAC treatment
was associated with lower risk of major bleeding compared
to VKA in our real-world population.
When looking at NOACs as a group for patients with
non-end-stage CKD, our results seem to be in accordance
with the existing literature. Effect of renal function on effi-
cacy and safety of NOACs vs. warfarin among AF patients
has been studied in the pivotal phase 3 NOAC trials, both
among patients with reduced renal function at baseline
and among patients with deteriorating renal function after
randomization. A review collected data from randomized
trials to compare safety and efficacy of NOACs vs. war-
farin. They included patients with AF and an eGFR be-
tween 15 and 60mL/min (CKD stages 3 and 4) and
concluded that NOACs were just as effective in stroke
prevention without causing an increased risk of bleeding,
primarily reflecting AF patients with CKD stage 3 [18].
Apixaban reduced risk of bleeding compared to warfarin
Fig. 2 Treatment initiation patterns of OAC among AF patients with CKD between 2011 and 2017
Table 2 Risk of events according to OAC in AF and CKD patients
Number
of events
Hazard ratio
(95%CI)
Standardized absolute
risk (95%CI)
Stroke/thromboembolism
VKA 21 1.00 (reference) 2.4% (1.4–3.5%)
NOAC 11 0.83 (0.39–1.78) 2.0% (0.8–3.3%)
Major bleeding
VKA 55 1.00 (reference) 5.9% (4.4–7.5%)
NOAC 15 0.47 (0.26–0.84) 2.8% (1.5–4.3%)
Myocardial infarction
VKA 22 1.00 (reference) 2.5% (1.5–3.7%)
NOAC 7 0.45 (0.18–1.11) 1.1% (0.4–2.2%)
All-cause mortality
VKA 183 1.00 (reference) 23.3% (20.2–26.3%)
NOAC 106 0.99 (0.77–1.26) 23.2% (19.4–27.0%)
Abbreviations: CI Confidence interval, OAC Oral anticoagulation, VKA Vitamin-K
antagonist, NOAC Nonvitamin K oral anticoagulant
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to a higher degree among patients with renal impairment
than among patients without renal impairment [7],
whereas dabigatran showed a significant trend towards
higher risk of major bleeding compared to warfarin among
patients with low renal function compared to patients
with normal renal function [19]. The majority of the
NOAC-treated study population (54.7%) received apixa-
ban and a minority (14.5%) received dabigatran. Our re-
sults could reflect the beneficial safety of apixaban among
patients with non-end-stage CKD found in trials, and ex-
tent the findings from randomized trials to a real-world
population.
Combining results from clinical trials and real-world
studies, NOACs have been shown to be as effective and
safe as VKA in AF patients with non-end-stage CKD,
but all pivotal phase 3 randomized trials of warfarin vs.
NOACs excluded patients with creatinine clearance
(CrCl) < 25 mL/min [6], and it is still not known whether
NOACs are safe and effective among these patients.
Renal function data was not available in our study co-
hort, but by looking at the kidney function distribution
in the comparable population, it seems reasonable to
hypothesize that a significant number of patients in our
study also had an eGFR< 30mL/min/1.73m2.
Our findings are also consistent with a recent retrospect-
ive cohort study that investigated the effects of apixaban
vs. warfarin in AF patients on dialysis [20]. They found
comparable efficacy with apixaban compared to warfarin,
but a significant 28% lower HR of major bleeding. The
results regarding use of NOACs in end-stage CKD are still
hypothesis-generating and ongoing randomized controlled
trials will most likely settle these questions.
Mortality risk among patients with AF and CKD
In our study the risk of dying of any cause was almost one
in four following the first year of treatment with NOAC or
VKA treatment (23.2% vs. 23.3%). Albeit we found a sig-
nificant lower risk of major bleeding and a non-significant
lower risk of stroke/TE and MI associated with NOAC
compared with VKA treatment, we did not find any signals
of a difference in the mortality risk between NOAC vs.
VKA treatment. Regarding the outcomes major bleeding,
stroke/TE, and MI, we adjusted the statistical analyses for
competing risk of death, but it was evident that our study
population comprising of vulnerable and frail individuals
with AF and CKD had a high risk of death, independent of
NOAC or VKA treatment. In routine clinical practice, the
high risk of death must be taken into account when man-
aging patients with AF and CKD. Also, even though there
was no difference in mortality risk between NOAC and
VKA treatment, a major bleeding event can be serious or
fatal, and the different bleeding risk with NOAC and VKA
treatment (2.8% vs. 5.9%) may be considered when initiat-
ing OAC treatment among these frail patients.
Strengths and limitations
In this nationwide study, we included all Danish citizens
on OAC with a diagnosis of both AF and CKD. We had
Fig. 3 Standardized absolute risk of event according to type of OAC among AF patients with CKD
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practically no loss to follow-up and, the majority of diag-
noses used, such as CKD, AF, bleedings, and strokes
have been validated [8]. Our study also had limitations.
Since creatinine values were not available after 2011, we
could not determine exact renal function for each pa-
tient in our study, which is a major limitation. For the
same reason, we were not able to determine if there was
a difference in renal function between the NOAC and
VKA population. This limitation makes it difficult to
draw definite conclusions from our study and the limita-
tion should be kept in mind when interpreting the re-
sults. Further research should be done to establish the
effects of NOAC in patients with AF and CKD. The
number of study outcomes for stroke/TE and MI are
limited, making it uncertain to draw conclusions for
those outcomes. The limited number of study outcomes
also prevented us from analyzing differences among the
individual types of NOAC. Some comorbidities such as
hypertension and diabetes were identified using data on
prescribed medicine, meaning that patients treated solely
with lifestyle changes could not be identified. Also, it
is possible that some patients were prescribed this
medication for other unknown purposes. The hyper-
tension definition, however, has previously been vali-
dated with a positive predictive value of 80% [14].
Finally, as in most observational studies, unmeasured
confounding or residual confounding affecting our re-
sults cannot be ruled out.
Conclusion
In patients with AF and CKD, treatment with NOAC
was associated with a lower risk of major bleeding, but
was not found to either decrease or increase the risk of
stroke/TE, MI or all-cause mortality compared to VKA.
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